NO951761L - Stabilt preparat for behandling av blodkoagulasjonssykdommer - Google Patents
Stabilt preparat for behandling av blodkoagulasjonssykdommerInfo
- Publication number
- NO951761L NO951761L NO951761A NO951761A NO951761L NO 951761 L NO951761 L NO 951761L NO 951761 A NO951761 A NO 951761A NO 951761 A NO951761 A NO 951761A NO 951761 L NO951761 L NO 951761L
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- blood coagulation
- coagulation disorders
- stable preparation
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4866—Protein C (3.4.21.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21006—Coagulation factor Xa (3.4.21.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Det beskrives et stabilt preparat som omfatter et protein som er bundet i og/eller på lipidvesikler, og som ble behandlet for inaktivering av potensielt tilstedeværende virus.Det beskrives videre frem-gangsmåter for fremstilling av et stabilt preparat for behandling av blod-koagulasjonssykdommer, hvori et protein er bundet i og/eller på lipidvesikler, og fremgangsmåten omfatter et trinn i hvilket proteinlipidkomplekset under-kastes en behandling for inaktivering av potensielt tilstedeværende virus.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4416166A DE4416166C2 (de) | 1994-05-06 | 1994-05-06 | Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen |
Publications (2)
Publication Number | Publication Date |
---|---|
NO951761D0 NO951761D0 (no) | 1995-05-05 |
NO951761L true NO951761L (no) | 1995-11-07 |
Family
ID=6517569
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO951761A NO951761L (no) | 1994-05-06 | 1995-05-05 | Stabilt preparat for behandling av blodkoagulasjonssykdommer |
Country Status (8)
Country | Link |
---|---|
US (1) | US5698677A (no) |
EP (1) | EP0680764A3 (no) |
JP (1) | JP3051650B2 (no) |
AT (1) | ATA76995A (no) |
CA (1) | CA2148746A1 (no) |
DE (1) | DE4416166C2 (no) |
FI (1) | FI952169A (no) |
NO (1) | NO951761L (no) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4416180C2 (de) * | 1994-05-06 | 1997-08-14 | Immuno Ag | Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen und Verfahren zur Herstellung dieses Präparats |
US6017891A (en) * | 1994-05-06 | 2000-01-25 | Baxter Aktiengesellschaft | Stable preparation for the treatment of blood coagulation disorders |
DE4430205A1 (de) * | 1994-08-26 | 1996-02-29 | Behringwerke Ag | Zusammensetzungen, die als Gegenmittel für Blut-Antikoagulanzien geeignet sind und deren Verwendung |
HUP9700603A3 (en) * | 1996-03-20 | 2001-08-28 | Baxter Ag | Pharmaceutical preparation for the treatment of blood coagulation disorders |
US6287590B1 (en) * | 1997-10-02 | 2001-09-11 | Esperion Therapeutics, Inc. | Peptide/lipid complex formation by co-lyophilization |
AT407484B (de) | 1997-11-12 | 2001-03-26 | Bio Prod & Bio Eng Ag | Arzneimittel zur förderung der wundheilung |
WO1999066939A1 (en) * | 1998-06-23 | 1999-12-29 | Marder Victor J | Phospholipid vesicle-tissue factor complex preparations and methods of making and using same |
US6258577B1 (en) | 1998-07-21 | 2001-07-10 | Gambro, Inc. | Method and apparatus for inactivation of biological contaminants using endogenous alloxazine or isoalloxazine photosensitizers |
US6277337B1 (en) | 1998-07-21 | 2001-08-21 | Gambro, Inc. | Method and apparatus for inactivation of biological contaminants using photosensitizers |
US6268120B1 (en) | 1999-10-19 | 2001-07-31 | Gambro, Inc. | Isoalloxazine derivatives to neutralize biological contaminants |
US6248353B1 (en) | 1999-12-10 | 2001-06-19 | Dade Behring Inc. | Reconstitution of purified membrane proteins into preformed liposomes |
TW590780B (en) | 2000-06-02 | 2004-06-11 | Gambro Inc | Additive solutions containing riboflavin |
US7648699B2 (en) | 2000-06-02 | 2010-01-19 | Caridianbct Biotechnologies, Llc | Preventing transfusion related complications in a recipient of a blood transfusion |
US7985588B2 (en) | 2000-06-02 | 2011-07-26 | Caridianbct Biotechnologies, Llc | Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light |
US9044523B2 (en) | 2000-06-15 | 2015-06-02 | Terumo Bct, Inc. | Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light |
US6596543B2 (en) | 2001-03-22 | 2003-07-22 | Dade Behring Inc. | Use of liposomes of defined composition and size for the preparation of prothrombin time reagents |
US7015193B2 (en) * | 2001-04-20 | 2006-03-21 | University Of Vermont | Compositions and methods to control bleeding |
US7125846B2 (en) | 2001-11-09 | 2006-10-24 | Novo Nordisk Healthcare A/G | Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides |
US20030232075A1 (en) * | 2002-05-06 | 2003-12-18 | University Of Minnesota, A Minnesota Corporation | Compositions for producing factor Xa |
EP2082748A1 (de) * | 2002-07-23 | 2009-07-29 | Bio & Bio Licensing SA | Thrombingenerierfähige und thrombinhältige pharmazeutische Wirkstoffzubereitungen und Arzneimittel |
EP1523327A1 (de) | 2002-07-23 | 2005-04-20 | Bio-Products & Bio-Engineering Aktiengesellschaft | Thrombingenerierfahige und thrombinhaltige pharmazeutische wirkstoffzubereitungen und arzneimittel |
US7671013B2 (en) | 2003-04-03 | 2010-03-02 | Canadian Blood Services, Inc. | Coagulation proteins, coagulation-anticoagulation protein complexes, derivatives thereof and their uses |
WO2004087198A1 (en) * | 2003-04-03 | 2004-10-14 | Canadian Blood Services | Use of coagulation proteins to lyse clots |
US8329184B2 (en) * | 2005-06-27 | 2012-12-11 | Glaxosmithkline Biologicals S.A. | Process for manufacturing vaccines |
DE102006008613A1 (de) | 2006-02-24 | 2007-08-30 | Dade Behring Marburg Gmbh | Stabilisierte Zubereitungen von Serin-Endopeptidasen, deren Herstellung und Verwendung |
CA2660310C (en) * | 2006-03-30 | 2015-04-21 | The Research Foundation Of State University Of New York | Compositions of less immunogenic and long-circulating protein-lipid complexes |
EP1939218A1 (en) * | 2006-12-29 | 2008-07-02 | Thrombotargets Europe, S.L. | Microvesicles derived from recombinant yeast having haemostatic activities and uses thereof |
GB201122430D0 (en) * | 2011-12-23 | 2012-02-08 | Xstalbio Ltd | Reconstitution method for high concentration dry protein formulation |
EP3065768B1 (en) * | 2013-11-04 | 2020-09-23 | The Regents of the University of California | Composition for use in treatment or prevention of conditions associated with bleeding or hypocoagulationcompostion |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4241046A (en) * | 1978-11-30 | 1980-12-23 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
AT368883B (de) * | 1980-07-22 | 1982-11-25 | Immuno Ag | Verfahren zur herstellung einer neuen blutgerinnungsfoerdernden praeparation auf basis von humanproteinen |
JPS5770814A (en) * | 1980-10-17 | 1982-05-01 | Isamu Horikoshi | Oral preparation of blood clotting eighth factor |
US4348384A (en) * | 1980-10-17 | 1982-09-07 | Dainippon Pharmaceutical Co., Ltd. | Pharmaceutical composition for oral administration containing coagulation factor VIII or IX |
GB2129685B (en) * | 1982-11-11 | 1985-11-13 | Nat Biolog Standards Board | Anti-haemophilic compositions |
US4610880A (en) * | 1983-06-27 | 1986-09-09 | Queen's University At Kingston | Composition for controlling hemophilia in mammals |
US4721618A (en) * | 1983-06-27 | 1988-01-26 | Queen's University At Kingston | Method for controlling bleeding |
AT389815B (de) * | 1984-03-09 | 1990-02-12 | Immuno Ag | Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten |
US5198349A (en) * | 1986-01-03 | 1993-03-30 | Genetics Institute, Inc. | Method for producing factor VIII:C and analogs |
US4937324A (en) * | 1987-02-06 | 1990-06-26 | Zymogenetics, Inc. | Chromatographic purification of human proteins having anticoagulant and anti-inflammatory activity |
WO1990003808A1 (en) * | 1988-10-07 | 1990-04-19 | The Liposome Company, Inc. | Heat treating liposomes |
AU5959990A (en) * | 1989-08-14 | 1991-04-03 | Queen's University At Kingston | Method for stimulating fibrinolytic effect |
DE3942933A1 (de) * | 1989-12-23 | 1991-06-27 | Boehringer Mannheim Gmbh | Verwendung von alkylphospholipiden als antivirale arzneimittel und neue phospholipid-derivate |
US5225537A (en) * | 1989-12-29 | 1993-07-06 | Zymogenetics, Inc. | Methods for producing hybrid phospholipid-binding proteins |
EP0443724B1 (en) * | 1990-02-20 | 1999-03-17 | Baxter International Inc. | Viral-safe purified human thrombin |
US5418130A (en) * | 1990-04-16 | 1995-05-23 | Cryopharm Corporation | Method of inactivation of viral and bacterial blood contaminants |
US5504064A (en) * | 1991-04-10 | 1996-04-02 | Oklahoma Medical Research Foundation | Treatment of bleeding with modified tissue factor in combination with an activator of FVII |
DE4325872C1 (de) * | 1993-08-02 | 1994-08-04 | Immuno Ag | Virusinaktivierte Faktor Xa-Präparation |
AU7384994A (en) * | 1993-08-06 | 1995-02-28 | Opperbas Holding B.V. | A method for high loading of vesicles with biopolymeric substances |
DE4416180C2 (de) * | 1994-05-06 | 1997-08-14 | Immuno Ag | Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen und Verfahren zur Herstellung dieses Präparats |
-
1994
- 1994-05-06 DE DE4416166A patent/DE4416166C2/de not_active Expired - Fee Related
-
1995
- 1995-05-05 US US08/435,128 patent/US5698677A/en not_active Expired - Lifetime
- 1995-05-05 EP EP95106821A patent/EP0680764A3/en not_active Withdrawn
- 1995-05-05 AT AT0076995A patent/ATA76995A/de not_active Application Discontinuation
- 1995-05-05 FI FI952169A patent/FI952169A/fi not_active Application Discontinuation
- 1995-05-05 NO NO951761A patent/NO951761L/no not_active Application Discontinuation
- 1995-05-05 CA CA002148746A patent/CA2148746A1/en not_active Abandoned
- 1995-05-08 JP JP7109458A patent/JP3051650B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
FI952169A (fi) | 1995-11-07 |
NO951761D0 (no) | 1995-05-05 |
DE4416166C2 (de) | 1997-11-20 |
US5698677A (en) | 1997-12-16 |
FI952169A0 (fi) | 1995-05-05 |
JPH07304658A (ja) | 1995-11-21 |
JP3051650B2 (ja) | 2000-06-12 |
DE4416166A1 (de) | 1995-11-09 |
EP0680764A2 (en) | 1995-11-08 |
EP0680764A3 (en) | 1998-01-28 |
CA2148746A1 (en) | 1995-11-07 |
ATA76995A (de) | 2002-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO951761L (no) | Stabilt preparat for behandling av blodkoagulasjonssykdommer | |
DK0429570T3 (da) | Osteoinducerende præparater | |
ATE289508T1 (de) | Butyrate derivaten zur behandlung von fibromyalgia und chronische müdigkeit-syndrom | |
DK0865294T3 (da) | Fremgangsmåder til reduktion eller bibeholdelse af reducerede niveauer afblodlipider under anvendelse af OB-proteinpræparater | |
ATE233738T1 (de) | Kleine moleküle anwendbar in der behandlung von entzündgskrankheiten | |
DE69027865D1 (de) | ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN | |
AU6909996A (en) | Methods and compositions for the selective modification of nucleic acids | |
NO963568D0 (no) | Farmasöytisk preparat for behandling av blodkoagulasjonssykdommer, fremgangsmåter for fremstilling av dette og dets anvendelse | |
DE69535758D1 (de) | Lipid-analoge zur behandlung von viralen infektionen | |
NO972475L (no) | Ny antitrombotisk formulering, fremgangsmåte for dens fremstilling og anvendelse derav | |
DE69631478D1 (de) | Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen | |
EE9700225A (et) | Meetod diabetes mellituse raviks, kasutades KKF | |
DE69606960T2 (de) | Adsorbent, Verfahren zu dessen Herstellung und Methode zur Behandlung von Fruchtsaft | |
DK0722344T3 (da) | Fremgangsmåde til virusinaktivering i nærvær af en polyether og et middel | |
ATE78397T1 (de) | Verwendung von p-chlorophenoxyazetat von n,ndimethylbiguanidzur behandlung von neuropathien und nervendegeneration. | |
ATE253589T1 (de) | Bmp-5-derivate | |
DE69309790D1 (de) | Cyclopentanperhydrophenanthren-17-beta-(3-Furyl)-3-Derivate und pharmazeutische Präparate davon, zur Behandlung von Kardiovaskulär-Erkrankungen | |
DE69621786D1 (de) | Aminotetralinderivat zur behandlung von herzkreislauferkrankung | |
EP0680763A3 (en) | Stable preparation for the treatment of blood coagulation disorders comprising an activated coagulation factor and lipid vesicles | |
NO950925D0 (no) | Preparat og fremgangsmåte for behandling av hårtap | |
DE69734349D1 (de) | Behandlung von knochenleiden mit adrenomedullin | |
ATE320263T1 (de) | Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie | |
DE69313534T2 (de) | Digitoxigenin und Dihydrodigitoxigenin 3-beta-Derivate und pharmazeutische Präparate davon, zur Behandlung von hypertonie | |
Nakajima et al. | New equipment for necrotic burn treatment using excimer laser irradiations | |
RU96117545A (ru) | Способ лечения диабетической ретинопатии |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |